Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18299363 | 0.80 | KIF11 (0.40) | — | |
| SCHEMBL30885855 | 0.71 | ALDH1A1 (0.42) | ALDH1A1HTTATMKDM4EL3MBTL1 | |
| SCHEMBL1335436 | 0.71 | ALDH1A1 (0.54) | ALDH1A1HTTATMKDM4E | |
| SCHEMBL28483927 | 0.69 | RORC (0.43) | — | |
| SCHEMBL30541890 | 0.68 | — | — | |
| SCHEMBL35211781 | 0.68 | RHEB (0.37) | ATMDAO | |
| SCHEMBL35211784 | 0.67 | KDM4E (0.39) | ALDH1A1HTTATMKDM4EDAO | |
| SCHEMBL30885828 | 0.67 | KDM4E (0.49) | ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL35211474 | 0.66 | PDE10A (0.34) | ALDH1A1HTTKDM4EERN1 | |
| SCHEMBL2909623 | 0.65 | CYP19A1 (0.46) | ALDH1A1KDM4EERN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125366-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125366-A1 | METHODS FOR TREATING CANCER | AKT2, AKT3, PIK3R5 | ALDH1A1 2246/4885HTT 2280/4885ATM 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.